Keywords:
Genital / Reproductive system male, Oncology, Other, Brachytherapy, Outcomes, Toxicity
Authors:
W. L. Ong, J. Millar
DOI:
10.26044/ranzcr2022/R-0140
Results
177 men were included in this study. Median follow-up was 60 months (IQR: 36-74 months).
URINARY FUNCTION
For overall urinary function, proportion of men with LAPERS was 2.3% (4/177), and baseline adjusted LAPERS was 2.3% (4/177). The prevalence of substantial urinary symptoms at 24 months and 60 months were 4.4% (5/170) and 1.8% (1/91) respectively (Figure 1). The 5-year cumulative incidence of substantial urinary symptoms was 17.8% (95%CI=12.7-24.6).
BOWEL FUNCTION
For overall bowel function, proportion of men with LAPERS was 2.3% (4/177), and baseline adjusted LAPERS was 1.7% (3/177). The prevalence of substantial bowel symptoms at 24 months and 60 months were 7.6% (5/169) and 3.6% (2/90) respectively (Figure 2). The 5-year cumulative incidence of substantial bowel symptoms was 16.2% (95%CI=11.3-23.2).
SEXUAL FUNCTION
For overall sexual function, proportion of men with LAPERS was 22% (39/177), and baseline adjusted LAPERS 15.8% (28/177). The prevalence of substantial sexual symptoms at 24 months and 60 months ears were 23.6% (39/126) and 25% (22/88) respectively (Figure 3). The 5-year cumulative incidence of substantial sexual symptoms was 51.9% (95%CI=44.0-60.3).